Group 1 - The core theme of the series of activities is "New Era, New Fund, New Value," aimed at promoting high-quality development of public funds in Beijing [1] - Public funds are actively responding to policy calls, enhancing their investment research layout, and demonstrating solid asset allocation capabilities in various hot investment sectors this year [1] - The biopharmaceutical sector is experiencing significant growth, showcasing diverse development potential across various sub-industries, including medical devices, innovative drugs, and traditional Chinese medicine [1] Group 2 - The innovative drug sector is expected to lead the pharmaceutical industry, with a strong performance anticipated through 2025, driven by favorable policies and improved fundamentals [2] - The Chinese government is supporting the pharmaceutical industry by optimizing the approval process for innovative drugs and including them in basic medical insurance, which enhances market opportunities for domestic companies [2] - The innovative drug industry is entering a new phase of "dual breakthroughs," with domestic companies transitioning from following global trends to leading them [2] Group 3 - 嘉实基金 has systematically planned its investment research capabilities and product layout in the innovative drug sector, focusing on high-growth areas [3] - The company has established a dedicated research team for the health sector, covering various sub-sectors of biopharmaceuticals, and has created an innovative drug industry chain research group to support investment decisions [3] - 嘉实基金 offers a diverse product line in the innovative drug sector, including passive investment options that track pharmaceutical indices and actively managed products targeting opportunities in A-shares and Hong Kong stocks [3]